The global gene panel market size was valued at USD 2.98 billion in 2023 and it is predicted to surpass around USD 15.11 billion by 2033 with a CAGR of 17.63% from 2024 to 2033. The Gene Panel Market is experiencing robust growth, driven by advancements in genomics, personalized medicine, and rising prevalence of genetic disorders. Gene panels, which are comprehensive collections of genetic tests targeting multiple genes associated with specific conditions, are becoming increasingly pivotal in diagnosing and managing genetic diseases.
The growth of the gene panel market is significantly influenced by the rising prevalence of genetic disorders and chronic diseases, which drives the demand for accurate and comprehensive diagnostic tools. As genetic conditions such as cancer, cardiovascular diseases, and rare genetic disorders become more prevalent, the need for gene panels that can identify mutations across multiple genes becomes increasingly critical. Additionally, advancements in genomic technologies, particularly next-generation sequencing (NGS), have greatly enhanced the efficiency and accuracy of gene panel testing. These technological improvements have made gene panels more accessible and cost-effective, further boosting their adoption. Moreover, the growing emphasis on personalized medicine is a major growth driver, as gene panels enable tailored treatment plans based on individual genetic profiles.
North America led the global gene panel market with a 37% share in 2023. The region has seen a surge in cancer research and inherited rare diseases, with significant increases in NGS-based and clinical applications. Government support, such as the CDC's $90 million funding for the Pathogen Genomics Centers of Excellence, is driving advancements in genomics technologies and public health applications.
| Attribute | North America |
| Market Value | USD 1.10 Billion |
| Growth Rate | 17.65% CAGR |
| Projected Value | USD 5.59 Billion |
Europe is expected to grow, supported by government policies and the development of new products. Germany’s genomeDE strategy and the UK's NHS commitment to whole genome sequencing are anticipated to drive market growth in the region.
Asia Pacific is projected to grow at the fastest CAGR. Increasing research on chronic diseases and the presence of key players in the region are significant drivers. The collaboration between Avesthagen Limited and Wipro L, announced in June 2022, aims to develop genetic testing solutions for various diseases, highlighting the region’s growth potential.
Test kits led the market with a substantial revenue share of 61% in 2023. The global trend towards self-utilization has increased demand for advanced diagnostic solutions for chronic diseases. For instance, in October 2023, China's National Medical Products Administration (NMPA) approved Geneseeq’s NSCLC tumor mutational burden test kit, which features a comprehensive gene panel covering 425 cancer-associated genes.
The testing services segment is projected to grow at the fastest rate from 2024 to 2033. Genetic testing services offer a wide range of tests that are crucial for making informed health decisions. These services include disease diagnosis, gene mutation identification, disease risk prediction, and guidance on treatment strategies. By integrating genetic testing into routine healthcare, these services provide convenient ordering options, flexible pricing, and professional genetic counseling for interpreting results.
Cancer risk assessment represented the largest segment, with a share of 55% in 2023. Gene panels provide a comprehensive alternative to multiple individual tests for identifying genetic risk factors associated with various cancers. For example, in October 2023, Invitae received FDA authorization for its Common Hereditary Cancers Panel, designed to detect germline variants related to hereditary cancer. The development of such panels is expected to further boost market growth.
The segment for diagnosing congenital diseases is anticipated to experience significant growth. Congenital diseases, which develop during fetal development, can be detected before birth or in early childhood. New tests, such as those introduced by CooperSurgical and Fulgent Genetics in February 2024, including the CBR Snapshot, CBR Portrait, and CBR Landscape tests, are enhancing the ability to screen for a variety of conditions like cardiovascular issues, cancer, and neonatal diabetes.
The amplicon-based approach dominated the market, holding 80% share in 2023. This technique, a target-based next-generation sequencing method, is widely used for examining genetic variations in specific genomic regions. It supports various applications, including genotyping, CRISP validation, SNP identification, and detection of indels. New products utilizing amplicon sequencing, such as PacBio's Onso platform introduced in October 2022, are expected to drive further market growth.
The hybridization-based approach is forecasted to grow at a significant CAGR. Known for its reproducibility and reliability, this method is often used for multigene panels. Integrated DNA Technologies, Inc.'s xGen Custom Hybridization Capture Panels, featuring high-fidelity oligos for targeted NGS research, exemplify this approach's effectiveness in sequencing a large number of genes, which will likely support segment growth.
Predesigned gene panels led the market with a revenue share of 67% in 2023. Increased investment in genomics and the development of new technologies for understanding biological systems are driving the growth of this segment. For instance, Vizgen's launch of predesigned MERFISH Gene Panels at the AACR Annual Meeting 2023 is expected to advance research in oncology and neuroscience.
Customized gene panels are anticipated to register significant growth. These panels allow for precise identification of nucleotide and copy number variations and are used for profiling various cell types and signaling pathways. In March 2024, 10x Genomics introduced a 5,000-Plex Gene Panel for Xenium, offering high customization for specific research needs. The development of such panels is expected to enhance market growth.
The academic and research institutes segment held the largest revenue share of over 43% in 2023 and is expected to see substantial growth. Increasing incidences of cancer and genetic disorders drive research activities, promoting the use of gene panels for pre-gestational, prenatal, neonatal screenings, and cancer diagnostics. In the U.S., genetic testing costs vary widely, influencing the accessibility and adoption of these tests.
Pharmaceutical and biotechnology companies experienced a rapid growth rate of 22.8%. This growth is attributed to rising demand for gene panels in research, increased government funding, and the focus on advanced drug development. For instance, in November 2023, Natera, Inc. and MSD formed an agreement allowing MSD to utilize Natera's real-world database of cancer patients, advancing oncology research.
By Product & Services
By Techniques
By Design
By End-use
By Application
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gene Panel Market
5.1. COVID-19 Landscape: Gene Panel Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gene Panel Market, By Product & Services
8.1. Gene Panel Market, by Product & Services, 2024-2033
8.1.1. Test Kits
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Testing Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Gene Panel Market, By Technique
9.1. Gene Panel Market, by Technique, 2024-2033
9.1.1. Amplicon Based Approach
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Hybridization Based Approach
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Gene Panel Market, By Design
10.1. Gene Panel Market, by Design, 2024-2033
10.1.1. Predesigned Gene Panel
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Customized Gene Panel
10.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Gene Panel Market, By Application
11.1. Gene Panel Market, by Application, 2024-2033
11.1.1. Cancer Risk Assessment
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Diagnosis of Congenital Diseases
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Pharmacogenetics
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Other Applications
11.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Gene Panel Market, By End-use
12.1. Gene Panel Market, by End-use, 2024-2033
12.1.1. Academic & Research Institutes
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Hospital & Diagnostic Laboratories
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Pharmaceutical & Biotechnology Companies
12.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Gene Panel Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.1.2. Market Revenue and Forecast, by Technique (2021-2033)
13.1.3. Market Revenue and Forecast, by Design (2021-2033)
13.1.4. Market Revenue and Forecast, by Application (2021-2033)
13.1.5. Market Revenue and Forecast, by End-use (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Design (2021-2033)
13.1.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.1.7. Market Revenue and Forecast, by End-use (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.1.8.3. Market Revenue and Forecast, by Design (2021-2033)
13.1.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.1.8.5. Market Revenue and Forecast, by End-use (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.2.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.3. Market Revenue and Forecast, by Design (2021-2033)
13.2.4. Market Revenue and Forecast, by Application (2021-2033)
13.2.5. Market Revenue and Forecast, by End-use (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Design (2021-2033)
13.2.7. Market Revenue and Forecast, by Application (2021-2033)
13.2.8. Market Revenue and Forecast, by End-use (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Design (2021-2033)
13.2.10. Market Revenue and Forecast, by Application (2021-2033)
13.2.11. Market Revenue and Forecast, by End-use (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Design (2021-2033)
13.2.12.4. Market Revenue and Forecast, by Application (2021-2033)
13.2.13. Market Revenue and Forecast, by End-use (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Design (2021-2033)
13.2.14.4. Market Revenue and Forecast, by Application (2021-2033)
13.2.15. Market Revenue and Forecast, by End-use (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.3.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.3. Market Revenue and Forecast, by Design (2021-2033)
13.3.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.5. Market Revenue and Forecast, by End-use (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Design (2021-2033)
13.3.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.7. Market Revenue and Forecast, by End-use (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Design (2021-2033)
13.3.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.9. Market Revenue and Forecast, by End-use (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Design (2021-2033)
13.3.10.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.10.5. Market Revenue and Forecast, by End-use (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Design (2021-2033)
13.3.11.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.11.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.4.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.3. Market Revenue and Forecast, by Design (2021-2033)
13.4.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Design (2021-2033)
13.4.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.7. Market Revenue and Forecast, by End-use (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Design (2021-2033)
13.4.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.9. Market Revenue and Forecast, by End-use (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Design (2021-2033)
13.4.10.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.10.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Design (2021-2033)
13.4.11.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.11.5. Market Revenue and Forecast, by End-use (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.5.2. Market Revenue and Forecast, by Technique (2021-2033)
13.5.3. Market Revenue and Forecast, by Design (2021-2033)
13.5.4. Market Revenue and Forecast, by Application (2021-2033)
13.5.5. Market Revenue and Forecast, by End-use (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Design (2021-2033)
13.5.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.5.7. Market Revenue and Forecast, by End-use (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product & Services (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Design (2021-2033)
13.5.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.5.8.5. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 14. Company Profiles
14.1. Agilent Technologies
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Illumina Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Qiagen Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Eurofins Genomics
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Foundation Medicine Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Guardant Health, Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Myriad Genetic Laboratories Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Cepheid
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Bio-Rad Laboratories, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers